text: Mylan once again defends King deal in face of Icahn stock buy PITTSBURGH Mylan Laboratories again reiterated its commitment to the estimated four (B) billion dollar acquisition of brand-name drug maker King Pharmaceuticals despite Wall Street financier Carl Icahn upping his stake in the company.